目的构建重组质粒柯萨奇病毒A组16型(coxsackievirus group A type 16,CA16)VP1,并进行原核表达及鉴定。方法用PCR方法扩增CA16 VP1序列,构建其重组表达质粒pET21b-CA16 VP1,并转入大肠杆菌E.coli BL21(DE3)进行诱导表达及纯化,SDS-PAG...目的构建重组质粒柯萨奇病毒A组16型(coxsackievirus group A type 16,CA16)VP1,并进行原核表达及鉴定。方法用PCR方法扩增CA16 VP1序列,构建其重组表达质粒pET21b-CA16 VP1,并转入大肠杆菌E.coli BL21(DE3)进行诱导表达及纯化,SDS-PAGE鉴定表达及纯化产物,间接ELISA方法检测重组蛋白CA16 VP1的抗原性和有效性。结果成功原核表达并纯化了CA16 VP1蛋白,可与小鼠抗CA16病毒血清特异性结合,与太原市老年人群中部分血清存在高反应性。结论 CA16 VP1蛋白获得成功表达,ELISA检测具有良好的抗原性和有效性,为CA16诊断试剂盒的研究奠定基础。展开更多
目的原核表达柯萨奇病毒A组16型(Coxsackievirus group A type 16,CA16)VP1蛋白,并检测其免疫原性。方法通过RT-PCR法从CA16病毒青岛株中扩增VP1基因,克隆至原核表达载体pET43.1a(+)中,构建重组表达质粒pET43.1a-VP1,转化感受态E.coli R...目的原核表达柯萨奇病毒A组16型(Coxsackievirus group A type 16,CA16)VP1蛋白,并检测其免疫原性。方法通过RT-PCR法从CA16病毒青岛株中扩增VP1基因,克隆至原核表达载体pET43.1a(+)中,构建重组表达质粒pET43.1a-VP1,转化感受态E.coli Rossatte(DE3),IPTG诱导表达。表达的重组CA16 VP1蛋白通过Ni柱亲和层析纯化后,采用不同剂量(5、10、20、40μg)免疫BALB/c小鼠,ELISA法检测血清中特异性IgG、IgG1、IgG2a、IgG2b、IgG3抗体效价,微量细胞病变抑制法检测血清中和抗体效价。结果重组表达质粒pET43.1a-VP1经双酶切及测序证实构建正确;表达的重组CA16 VP1蛋白相对分子质量约为34 000,主要以包涵体形式存在,表达量占菌体总蛋白的15%;纯化的重组CA16 VP1蛋白纯度可达95%以上,可与猴CA16抗血清反应;不同剂量的重组CA16 VP1蛋白免疫BALB/c小鼠,可诱导产生CA16特异性抗体,血清中总IgG、IgG1、IgG2a、IgG2b、IgG3抗体效价均明显高于对照组,且抗体效价与免疫剂量存在一定的量效关系;各剂量CA16 VP1组免疫小鼠血清中和抗体效价均小于1∶8。结论已成功在大肠杆菌中表达了重组CA16 VP1蛋白,纯化的重组蛋白可诱导小鼠特异性体液免疫应答,为进一步研究CA16的结构、功能及相关疫苗的研制奠定了基础。展开更多
目的 建立柯萨奇病毒A组16型（Coxsackievirus group A type 16,CA16）抗原定量检测的ELISA方法,用于CA16疫苗中抗原的定量检测。方法 以纯化的CA16病毒颗粒作为免疫原,分别免疫家兔和BALB/c小鼠,制备抗CA16多克隆抗体和单克隆抗体。以...目的 建立柯萨奇病毒A组16型（Coxsackievirus group A type 16,CA16）抗原定量检测的ELISA方法,用于CA16疫苗中抗原的定量检测。方法 以纯化的CA16病毒颗粒作为免疫原,分别免疫家兔和BALB/c小鼠,制备抗CA16多克隆抗体和单克隆抗体。以抗CA16多抗作为包被抗体,经HRP酶标记的单抗作为酶标抗体,建立CA16抗原定量检测的双抗体夹心ELISA方法,确定该方法的线性范围,并进行准确度、精密度、稳定性及特异性验证。用建立的方法检测CA16疫苗原液制备过程样品中CA16抗原含量。结果 以抗CA16多抗为包被抗体,针对74株不同基因型的CA16的ELISA检测结果均为阳性,该抗CA16单抗的广谱性较好。该方法的线性范围为23.4～750 ng/ml,R2跃0.99,最小检出量为23.4 ng/ml;样品回收率在89%～108%之间,CV约15%,准确度和精密度较好;抗体包被板干燥后于37℃放置6 d,CV约20%,稳定性较好;PV纯化样品、EV71收获液、Vero细胞样品中抗原的A值均小于cutoff值,特异性较好。随着CA16疫苗制备过程的不断进行,中间品1-4比活分别为0.44、0.64、92.13和1 239.03,呈逐渐上升趋势。结论 建立了CA16抗原定量检测的双抗体夹心ELISA方法,该方法准确度、精密度高,稳定性及特异性较好,为CA16疫苗的研制及工艺开发奠定了基础。展开更多
目的对引起手足口病（hand,foot and mouth disease,HFMD）的重要病原体柯萨奇病毒A组16型（coxsackievirus group A type16,CA16）临床分离株的生物学特性进行分析,为后续的疫苗研发奠定基础。方法从昆明地区HFMD临床疑似患者178份咽...目的对引起手足口病（hand,foot and mouth disease,HFMD）的重要病原体柯萨奇病毒A组16型（coxsackievirus group A type16,CA16）临床分离株的生物学特性进行分析,为后续的疫苗研发奠定基础。方法从昆明地区HFMD临床疑似患者178份咽拭子及粪便标本中分离并鉴定CA16毒株,并对病毒的生长特性、蚀斑形态以及对乳鼠的致病性等生物学特性进行分析。结果共分离出7株CA16病毒：KM1、KM15、KM154、KM165、KM168、KM263、KM881,均属于B1亚型;病毒在Vero细胞上增殖较快,多数毒株4～6 d即可达到增殖高峰,但感染性滴度差别较大,最低为4.75 lgCCID50/ml,而最高可达7.78 lgCCID50/ml;各毒株在Vero细胞上培养相同时间形成的蚀斑形态不同,其中KM15、KM154、KM168蚀斑呈圆形,针尖样大小,边缘较清晰,KM1、KM881、KM263、KM165蚀斑较大,不规则,边缘较模糊;各毒株毒力均较强,经乳鼠颅内注射后,乳鼠均于3～6 d陆续开始发病,除KM168、KM154、KM15组乳鼠为不同程度的发病及死亡外,其他组乳鼠发病率及病毒致死性死亡率均达100%;各毒株对乳鼠的脑、心肌、肺、肌肉、脊髓和肝脏等组织均有不同程度的损伤,其中损伤较严重的组织为脑和肌肉。结论分离的CA16毒株对Vero细胞均具有良好的适应性,蚀斑清晰,毒力较强,且多数毒株感染性滴度较高,可用于CA16病毒致病机理的研究及疫苗的研发。展开更多
Coxsackievirus A16(CA16) is one of the major causes of hand, foot, and mouth disease(HFMD) worldwide, which is a common illness that affects children. The frequent occurrence of HFMD outbreaks has become a serious pub...Coxsackievirus A16(CA16) is one of the major causes of hand, foot, and mouth disease(HFMD) worldwide, which is a common illness that affects children. The frequent occurrence of HFMD outbreaks has become a serious public health problem in Asia. Therefore, it is important to understand the pathogenesis and replication of CA16. In this study, a stable infectious c DNA clone of an epidemic strain of Coxsackievirus A16(CA16) was assembled, and subsequently a reporter virus(e GFP-CA16) was constructed by inserting the e GFP gene between the 5'-UTR and the N-terminus of VP4, with the addition of a 2A protease cleavage site(ITTLG) at its C-terminus. This was transfected into Vero cells to generate infectious recombinant viruses. The growth characteristics and plaque morphology, in vitro, in mammalian cells were found to be indistinguishable between the parental and recombinant viruses. Although the e GFP-CA16 showed smaller plaque size as compared to recombinant CA16, both were found to exhibit similar growth trends and EC50 of NITD008. In summary, this stable infectious c DNA clone should provide a valuable experimental system to study CA16 infection and host response. The e GFP-CA16 is expected to provide a powerful tool to monitor e GFP expression in infected cells and to evaluate the antiviral activity of potential antiviral agents in the treatment of CA16 infections.展开更多
文摘目的构建重组质粒柯萨奇病毒A组16型(coxsackievirus group A type 16,CA16)VP1,并进行原核表达及鉴定。方法用PCR方法扩增CA16 VP1序列,构建其重组表达质粒pET21b-CA16 VP1,并转入大肠杆菌E.coli BL21(DE3)进行诱导表达及纯化,SDS-PAGE鉴定表达及纯化产物,间接ELISA方法检测重组蛋白CA16 VP1的抗原性和有效性。结果成功原核表达并纯化了CA16 VP1蛋白,可与小鼠抗CA16病毒血清特异性结合,与太原市老年人群中部分血清存在高反应性。结论 CA16 VP1蛋白获得成功表达,ELISA检测具有良好的抗原性和有效性,为CA16诊断试剂盒的研究奠定基础。
文摘目的原核表达柯萨奇病毒A组16型(Coxsackievirus group A type 16,CA16)VP1蛋白,并检测其免疫原性。方法通过RT-PCR法从CA16病毒青岛株中扩增VP1基因,克隆至原核表达载体pET43.1a(+)中,构建重组表达质粒pET43.1a-VP1,转化感受态E.coli Rossatte(DE3),IPTG诱导表达。表达的重组CA16 VP1蛋白通过Ni柱亲和层析纯化后,采用不同剂量(5、10、20、40μg)免疫BALB/c小鼠,ELISA法检测血清中特异性IgG、IgG1、IgG2a、IgG2b、IgG3抗体效价,微量细胞病变抑制法检测血清中和抗体效价。结果重组表达质粒pET43.1a-VP1经双酶切及测序证实构建正确;表达的重组CA16 VP1蛋白相对分子质量约为34 000,主要以包涵体形式存在,表达量占菌体总蛋白的15%;纯化的重组CA16 VP1蛋白纯度可达95%以上,可与猴CA16抗血清反应;不同剂量的重组CA16 VP1蛋白免疫BALB/c小鼠,可诱导产生CA16特异性抗体,血清中总IgG、IgG1、IgG2a、IgG2b、IgG3抗体效价均明显高于对照组,且抗体效价与免疫剂量存在一定的量效关系;各剂量CA16 VP1组免疫小鼠血清中和抗体效价均小于1∶8。结论已成功在大肠杆菌中表达了重组CA16 VP1蛋白,纯化的重组蛋白可诱导小鼠特异性体液免疫应答,为进一步研究CA16的结构、功能及相关疫苗的研制奠定了基础。
文摘目的 建立柯萨奇病毒A组16型（Coxsackievirus group A type 16,CA16）抗原定量检测的ELISA方法,用于CA16疫苗中抗原的定量检测。方法 以纯化的CA16病毒颗粒作为免疫原,分别免疫家兔和BALB/c小鼠,制备抗CA16多克隆抗体和单克隆抗体。以抗CA16多抗作为包被抗体,经HRP酶标记的单抗作为酶标抗体,建立CA16抗原定量检测的双抗体夹心ELISA方法,确定该方法的线性范围,并进行准确度、精密度、稳定性及特异性验证。用建立的方法检测CA16疫苗原液制备过程样品中CA16抗原含量。结果 以抗CA16多抗为包被抗体,针对74株不同基因型的CA16的ELISA检测结果均为阳性,该抗CA16单抗的广谱性较好。该方法的线性范围为23.4～750 ng/ml,R2跃0.99,最小检出量为23.4 ng/ml;样品回收率在89%～108%之间,CV约15%,准确度和精密度较好;抗体包被板干燥后于37℃放置6 d,CV约20%,稳定性较好;PV纯化样品、EV71收获液、Vero细胞样品中抗原的A值均小于cutoff值,特异性较好。随着CA16疫苗制备过程的不断进行,中间品1-4比活分别为0.44、0.64、92.13和1 239.03,呈逐渐上升趋势。结论 建立了CA16抗原定量检测的双抗体夹心ELISA方法,该方法准确度、精密度高,稳定性及特异性较好,为CA16疫苗的研制及工艺开发奠定了基础。
文摘目的对引起手足口病（hand,foot and mouth disease,HFMD）的重要病原体柯萨奇病毒A组16型（coxsackievirus group A type16,CA16）临床分离株的生物学特性进行分析,为后续的疫苗研发奠定基础。方法从昆明地区HFMD临床疑似患者178份咽拭子及粪便标本中分离并鉴定CA16毒株,并对病毒的生长特性、蚀斑形态以及对乳鼠的致病性等生物学特性进行分析。结果共分离出7株CA16病毒：KM1、KM15、KM154、KM165、KM168、KM263、KM881,均属于B1亚型;病毒在Vero细胞上增殖较快,多数毒株4～6 d即可达到增殖高峰,但感染性滴度差别较大,最低为4.75 lgCCID50/ml,而最高可达7.78 lgCCID50/ml;各毒株在Vero细胞上培养相同时间形成的蚀斑形态不同,其中KM15、KM154、KM168蚀斑呈圆形,针尖样大小,边缘较清晰,KM1、KM881、KM263、KM165蚀斑较大,不规则,边缘较模糊;各毒株毒力均较强,经乳鼠颅内注射后,乳鼠均于3～6 d陆续开始发病,除KM168、KM154、KM15组乳鼠为不同程度的发病及死亡外,其他组乳鼠发病率及病毒致死性死亡率均达100%;各毒株对乳鼠的脑、心肌、肺、肌肉、脊髓和肝脏等组织均有不同程度的损伤,其中损伤较严重的组织为脑和肌肉。结论分离的CA16毒株对Vero细胞均具有良好的适应性,蚀斑清晰,毒力较强,且多数毒株感染性滴度较高,可用于CA16病毒致病机理的研究及疫苗的研发。
基金supported by the Science and Technology Plan Projects of Wuhan (grant No. 2013060501010157)
文摘Coxsackievirus A16(CA16) is one of the major causes of hand, foot, and mouth disease(HFMD) worldwide, which is a common illness that affects children. The frequent occurrence of HFMD outbreaks has become a serious public health problem in Asia. Therefore, it is important to understand the pathogenesis and replication of CA16. In this study, a stable infectious c DNA clone of an epidemic strain of Coxsackievirus A16(CA16) was assembled, and subsequently a reporter virus(e GFP-CA16) was constructed by inserting the e GFP gene between the 5'-UTR and the N-terminus of VP4, with the addition of a 2A protease cleavage site(ITTLG) at its C-terminus. This was transfected into Vero cells to generate infectious recombinant viruses. The growth characteristics and plaque morphology, in vitro, in mammalian cells were found to be indistinguishable between the parental and recombinant viruses. Although the e GFP-CA16 showed smaller plaque size as compared to recombinant CA16, both were found to exhibit similar growth trends and EC50 of NITD008. In summary, this stable infectious c DNA clone should provide a valuable experimental system to study CA16 infection and host response. The e GFP-CA16 is expected to provide a powerful tool to monitor e GFP expression in infected cells and to evaluate the antiviral activity of potential antiviral agents in the treatment of CA16 infections.
